Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

PLoS medicine - 1 Feb 2007

Galipeau Patricia C, Li Xiaohong, Blount Patricia L, Maley Carlo C, Sanchez Carissa A, Odze Robert D, Ayub Kamran, Rabinovitch Peter S, Vaughan Thomas L, Reid Brian J

Abstract excerpt

BACKGROUND: Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett's esophagus (BE), conditions for which aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemopreventive agents; however, little is known about the ability of a biomarker panel to predict...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aneuploidy
Share to Anti-Inflammatory Agents, Non-Steroidal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Barrett Esophagus

Share to Chromosomes, Human, Pair 17

Share to Chromosomes, Human, Pair 9

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Esophageal Neoplasms

Share to Esophagus

Source

Open in PubMed Open full text

Identifiers

PMID: 17326708
DOI: 10.1371/journal.pmed.0040067
PMCID: PMC1808095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.PMID 17326708Read ↗

NSAID use and somatic exomic mutations in Barrett's esophagus.Semantic proximity Read ↗

Molecular Abnormalities and Carcinogenesis in Barrett’s Esophagus: Implications for Cancer Treatment and PreventionSemantic proximity Read ↗

Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.Semantic proximity Read ↗

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.Semantic proximity Read ↗

p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterationsSemantic proximity Read ↗

Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.Semantic proximity Read ↗

Meta-analysis of biomarkers predicting risk of malignant progression in Barrett's oesophagus.Semantic proximity Read ↗

NSAIDs modulate clonal evolution in Barrett's esophagus.Semantic proximity Read ↗

p16 mutation spectrum in the premalignant condition Barrett's esophagus.Semantic proximity Read ↗

Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression riskSemantic proximity Read ↗

Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.